[go: up one dir, main page]

HK1208437A1 - Antibacterial quinoline derivatives - Google Patents

Antibacterial quinoline derivatives Download PDF

Info

Publication number
HK1208437A1
HK1208437A1 HK15108797.1A HK15108797A HK1208437A1 HK 1208437 A1 HK1208437 A1 HK 1208437A1 HK 15108797 A HK15108797 A HK 15108797A HK 1208437 A1 HK1208437 A1 HK 1208437A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
compound
formula
compounds
amino
Prior art date
Application number
HK15108797.1A
Other languages
English (en)
Chinese (zh)
Inventor
Jérôme Emile Georges GUILLEMONT
David Francis Alain LANÇOIS
Ismet Dorange
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38126091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1208437(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HK1208437A1 publication Critical patent/HK1208437A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
HK15108797.1A 2006-12-06 2015-09-10 Antibacterial quinoline derivatives HK1208437A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125499 2006-12-06
EP06125499.1 2006-12-06

Publications (1)

Publication Number Publication Date
HK1208437A1 true HK1208437A1 (en) 2016-03-04

Family

ID=38126091

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108797.1A HK1208437A1 (en) 2006-12-06 2015-09-10 Antibacterial quinoline derivatives

Country Status (33)

Country Link
US (1) US8415475B2 (xx)
EP (1) EP2099758B1 (xx)
JP (1) JP5466011B2 (xx)
KR (1) KR101490222B1 (xx)
CN (2) CN101553470A (xx)
AP (1) AP2479A (xx)
AR (1) AR064151A1 (xx)
AU (1) AU2007328887B2 (xx)
BR (1) BRPI0720220B8 (xx)
CA (1) CA2669819C (xx)
CL (1) CL2007003514A1 (xx)
CY (1) CY1117766T1 (xx)
DK (1) DK2099758T3 (xx)
EA (1) EA016733B1 (xx)
ES (1) ES2573689T3 (xx)
HK (1) HK1208437A1 (xx)
HR (1) HRP20160585T1 (xx)
HU (1) HUE028769T2 (xx)
IL (1) IL199083A (xx)
JO (1) JO3271B1 (xx)
ME (1) ME02498B (xx)
MX (1) MX2009005978A (xx)
MY (1) MY181645A (xx)
NO (1) NO341983B1 (xx)
NZ (1) NZ576823A (xx)
PL (1) PL2099758T3 (xx)
PT (1) PT2099758E (xx)
RS (1) RS54794B1 (xx)
SI (1) SI2099758T1 (xx)
TW (1) TWI406659B (xx)
UA (1) UA100972C2 (xx)
WO (1) WO2008068267A1 (xx)
ZA (1) ZA200903950B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2841426T (pt) 2012-04-27 2016-11-23 Janssen Pharmaceutica Nv Derivados de quinolina antibacterianos
WO2013160435A1 (en) 2012-04-27 2013-10-31 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
ES2632269T3 (es) 2012-10-16 2017-09-12 Janssen Pharmaceutica Nv Moduladores de quinolinailo enlazados a metileno de ROR-gamma-t
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
KR20150070350A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. Ror-감마-t의 페닐 결합 퀴놀리닐 조절제
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CN105873439A (zh) 2013-10-15 2016-08-17 詹森药业有限公司 RORγt的烷基连接的喹啉基调节剂
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
WO2016008381A1 (zh) * 2014-07-14 2016-01-21 辰欣药业股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
DK3250182T3 (da) * 2015-01-27 2023-06-26 Janssen Pharmaceutica Nv Dispergible sammensætninger
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
EP4148053A1 (en) * 2016-03-07 2023-03-15 The Global Alliance for TB Drug Development, Inc. Antibacterial compounds and uses thereof
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
JP2021511364A (ja) * 2018-01-29 2021-05-06 カディラ ヘルスケア リミティド 抗菌剤として有用な複素環式化合物
IL302095A (en) * 2020-10-22 2023-06-01 Lunella Biotech Inc Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503411A (ja) * 1996-10-28 2001-03-13 ディパートメント オブ ジ アーミー，ユー．エス．ガバメント 抗生物質耐性感染症の処置のための化合物、組成物および方法
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
AU2005206330B2 (en) 2004-01-23 2010-09-16 Janssen Pharmaceutica N.V. Substituted quinolines and their use as mycobacterial inhibitors
ES2333730T3 (es) * 2004-01-23 2010-02-26 Janssen Pharmaceutica Nv Derivados de quinolina y uso de los mismos como inhibidores de micobacterias.
AU2005210036B2 (en) 2004-01-29 2010-12-23 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
ES2306146T3 (es) * 2004-05-28 2008-11-01 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
HRP20171388T1 (hr) 2004-09-28 2017-11-03 Janssen Pharmaceutica N.V. Vezna domena bakterijske atp sintaze
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
EA016733B1 (ru) 2012-07-30
JO3271B1 (ar) 2018-09-16
HRP20160585T1 (hr) 2016-06-17
BRPI0720220B8 (pt) 2021-05-25
NO20092542L (no) 2009-08-25
MX2009005978A (es) 2009-06-16
AU2007328887B2 (en) 2013-01-17
AP2479A (en) 2012-09-27
JP2010511668A (ja) 2010-04-15
WO2008068267A1 (en) 2008-06-12
TW200838528A (en) 2008-10-01
CA2669819C (en) 2016-08-30
AP2009004874A0 (en) 2009-06-30
AR064151A1 (es) 2009-03-18
BRPI0720220B1 (pt) 2020-06-09
CN104744361A (zh) 2015-07-01
CL2007003514A1 (es) 2008-07-11
AU2007328887A1 (en) 2008-06-12
BRPI0720220A2 (pt) 2013-12-24
ES2573689T3 (es) 2016-06-09
EP2099758B1 (en) 2016-03-09
EA200970535A1 (ru) 2009-10-30
MY181645A (en) 2020-12-30
ME02498B (me) 2017-02-20
ZA200903950B (en) 2010-08-25
UA100972C2 (ru) 2013-02-25
RS54794B1 (sr) 2016-10-31
TWI406659B (zh) 2013-09-01
PL2099758T3 (pl) 2016-08-31
NZ576823A (en) 2012-01-12
EP2099758A1 (en) 2009-09-16
CA2669819A1 (en) 2008-06-12
IL199083A (en) 2014-08-31
CN104744361B (zh) 2021-06-08
US8415475B2 (en) 2013-04-09
KR101490222B1 (ko) 2015-02-05
US20100048566A1 (en) 2010-02-25
DK2099758T3 (en) 2016-06-13
IL199083A0 (en) 2010-03-28
SI2099758T1 (sl) 2016-07-29
PT2099758E (pt) 2016-06-02
NO341983B1 (no) 2018-03-05
KR20090086604A (ko) 2009-08-13
CN101553470A (zh) 2009-10-07
HUE028769T2 (en) 2017-01-30
CY1117766T1 (el) 2017-05-17
JP5466011B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
CN104744361B (zh) 抗菌的喹啉衍生物
EP2099762B1 (en) Antibacterial quinoline derivatives
EP2841425B1 (en) Antibacterial quinoline derivatives
EP2099759B1 (en) Antibacterial quinoline derivatives
EP2099760B1 (en) Antibacterial quinoline derivatives
EP2086941B1 (en) Antibacterial quinoline derivatives
EP2099761B1 (en) Antibacterial quinoline derivatives
AU2013254670A1 (en) Antibacterial quinoline derivatives
HK1137435A (zh) 抗菌的喹啉衍生物
HK1137428B (en) Antibacterial quinoline derivatives
HK1137433B (en) Antibacterial quinoline derivatives
HK1137431B (en) Antibacterial quinoline derivatives
HK1137441B (en) Antibacterial quinoline derivatives
HK1205514B (zh) 抗菌的喹啉衍生物
HK1137437B (en) Antibacterial quinoline derivatives